D. Jodrell

发表

Enhanced oxaliplatin-induced apoptosis following antisense Bcl-xl down-regulation is p53 and Bax dependent: Genetic evidence for specificity of the antisense effect.

R. L. Hayward, J. S. Macpherson, J. Cummings, 2004, Molecular cancer therapeutics.

Investigation of the role of Bax, p21/Waf1 and p53 as determinants of cellular responses in HCT116 colorectal cancer cells exposed to the novel cytotoxic ruthenium(II) organometallic agent, RM175

S. Guichard, R. L. Hayward, J. S. Macpherson, 2005, Cancer Chemotherapy and Pharmacology.

A Highly Porous Metal-Organic Framework System to Deliver Payloads for Gene Knockdown

Marcus J. Fantham, C. Kaminski, O. Farha, 2019, Chem.

Loss of the interleukin-6 receptor causes immunodeficiency, atopy, and abnormal inflammatory responses

Kenneth G. C. Smith, S. Tavaré, M. Brown, 2019, The Journal of experimental medicine.

Adaptive designs for dual-agent phase I dose-escalation studies

Michael J. Sweeting, Graham M. Wheeler, Adrian P. Mander, 2013, Nature Reviews Clinical Oncology.

Glucuronidation as a mechanism of intrinsic drug resistance in colon cancer cells: contribution of drug transport proteins.

J. Cummings, J. Smyth, D. Jodrell, 2004, Biochemical pharmacology.

nab-Paclitaxel potentiates gemcitabine activity by reducing cytidine deaminase levels in a mouse model of pancreatic cancer.

D. Tuveson, D. Jodrell, K. Frese, 2012, Cancer discovery.

747TiPSCHEDULING NAB-PACLITAXEL WITH GEMCITABINE (SIEGE): RANDOMISED PHASE II TRIAL TO INVESTIGATE TWO DIFFERENT SCHEDULES OF NAB-PACLITAXEL (ABX) COMBINED WITH GEMCITABINE (GEM) AS FIRST LINE TREATMENT FOR METASTATIC PANCREATIC ADENOCARCINOMA (PDAC).

D. Jodrell, W. Qian, J. Valle, 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

Understanding Hematological Toxicities Using Mathematical Modeling

J. Mettetal, D. Jodrell, J. Yates, 2018, Clinical pharmacology and therapeutics.

CSF1R+ Macrophages Sustain Pancreatic Tumor Growth through T Cell Suppression and Maintenance of Key Gene Programs that Define the Squamous Subtype

A. Biankin, S. Barry, E. McGhee, 2018, Cell reports.

Developing and piloting a nurse-led model of follow-up in the multidisciplinary management of colorectal cancer.

D. Jodrell, G. Knowles, L. Sherwood, 2007, European journal of oncology nursing : the official journal of European Oncology Nursing Society.

Size-tuneable and immunocompatible polymer nanocarriers for drug delivery in pancreatic cancer

D. Jodrell, L. Fruk, H. Rahmoune, 2022, Nanoscale.

The mechanism of action of Kahalalide F: variable cell permeability in human hepatoma cell lines.

S. Guichard, J. Smyth, D. Jodrell, 2005, European journal of cancer.

Quantifying Drug‐Induced Bone Marrow Toxicity Using a Novel Haematopoiesis Systems Pharmacology Model

J. Mettetal, D. Jodrell, J. Yates, 2019, CPT: pharmacometrics & systems pharmacology.

Longitudinal quality of life and quality adjusted survival in a randomised controlled trial comparing six months of bolus fluorouracil/leucovorin vs. twelve weeks of protracted venous infusion fluorouracil as adjuvant chemotherapy for colorectal cancer.

T. Hickish, A. Norman, D. Tait, 2005, European journal of cancer.

A novel method for quantification of gemcitabine and its metabolites 2′,2′-difluorodeoxyuridine and gemcitabine triphosphate in tumour tissue by LC–MS/MS: comparison with 19F NMR spectroscopy

D. Tuveson, J. Griffiths, K. Olive, 2011, Cancer Chemotherapy and Pharmacology.

Population Pharmacokinetics and Pharmacodynamics of Paclitaxel and Carboplatin in Ovarian Cancer Patients: A Study by the European Organization for Research and Treatment of Cancer-Pharmacology and Molecular Mechanisms Group and New Drug Development Group

H. Hollema, A. Boddy, D. Richel, 2007, Clinical Cancer Research.

A comparison of methods for limited-sampling strategy design using data from a phase I trial of the anthrapyrazole DuP-941

L. Murray, D. Jodrell, M. Egorin, 1996, Cancer Chemotherapy and Pharmacology.

Cancer Therapy : Clinical A Phase 1 Study of AS 1409 , a Novel Antibody-Cytokine Fusion Protein , in Patients with Malignant Melanoma or Renal Cell Carcinoma

G. Acton, J. Spicer, D. Jodrell, 2011 .

Time-dependent cytotoxicity induced by SJG-136 (NSC 694501): influence of the rate of interstrand cross-link formation on DNA damage signaling

S. Guichard, J. S. Macpherson, D. Jodrell, 2006, Molecular Cancer Therapeutics.

ERβ isoform expression in colorectal carcinoma: an in vivo and in vitro study of clinicopathological and molecular correlates

D. Harrison, R. Malcomson, D. Jodrell, 2005, The Journal of pathology.

Depletion of Macrophages Improves Therapeutic Response to Gemcitabine in Murine Pancreas Cancer

M. Buchholz, D. Jodrell, V. Ellenrieder, 2020, Cancers.

Short hairpin RNAs targeting Bcl-xL modulate senescence and apoptosis following SN-38 and irinotecan exposure in a colon cancer model

S. Guichard, J. S. Macpherson, D. Jodrell, 2007, Cancer Chemotherapy and Pharmacology.

Cancer Immunotherapy Trials Underutilize Immune Response Monitoring

D. Fearon, D. Jodrell, T. Janowitz, 2017, The Oncologist.

A clinical study assessing the tolerability and biological effects of infliximab, a TNF-alpha inhibitor, in patients with advanced cancer.

C. Sturgeon, F. Balkwill, J. Smyth, 2008, Annals of oncology : official journal of the European Society for Medical Oncology.

Phase II studies of polymer-doxorubicin (PK1, FCE28068) in the treatment of breast, lung and colorectal cancer.

D. Kerr, D. Rea, D. Bissett, 2009, International journal of oncology.

Platinum distribution in malignant glioma following intraoperative intravenous infusion of carboplatin.

I. Whittle, D. Jodrell, M. Reid, 1999, British journal of neurosurgery.

A randomised comparison between 6 months of bolus fluorouracil/leucovorin and 12 weeks of protracted venous infusion fluorouracil as adjuvant treatment in colorectal cancer.

T. Hickish, A. Norman, D. Tait, 2005, Annals of oncology : official journal of the European Society for Medical Oncology.

Twelve weeks of protracted venous infusion of fluorouracil (5-FU) is as effective as 6 months of bolus 5-FU and folinic acid as adjuvant treatment in colorectal cancer

T. Hickish, A. Norman, D. Tait, 2003, British Journal of Cancer.

Simultaneous determination of capecitabine and its metabolites by HPLC and mass spectrometry for preclinical and clinical studies.

S. Guichard, D. Jodrell, I. Mayer, 2005, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

A phase I-II study of N-(phosphonacetyl)-L-aspartic acid (PALA) added to 5-fluorouracil and folinic acid in advanced colorectal cancer.

D. Kerr, S. Kaye, D. Jodrell, 1994, European journal of cancer.

Gene expression predicts differential capecitabine metabolism, impacting on both pharmacokinetics and antitumour activity.

S. Guichard, J. S. Macpherson, D. Jodrell, 2008, European journal of cancer.

Formula-based dosing for carboplatin.

D. Jodrell, 1999, European journal of cancer.

Population pharmacokinetics of gentamicin in patients with cancer.

D. Jodrell, A. Thomson, H. Elliott, 2002, British journal of clinical pharmacology.

The perceived information needs of patients receiving adjuvant chemotherapy for surgically resected colorectal cancer

A. Cull, D. Jodrell, A. Tierney, 1999 .

Prognosis without treatment as a modifier in health economic assessments

D. Webb, R. Camidge, D. Jodrell, 2005, BMJ : British Medical Journal.

How many cisplatin administration protocols does your department use?

D. Jodrell, M. Mackean, A. Greystoke, 2010, European journal of cancer care.

Gemcitabine diphosphate choline is a major metabolite linked to the Kennedy pathway in pancreatic cancer models in vivo

D. Tuveson, J. Griffiths, D. Jodrell, 2014, British Journal of Cancer.

Phase 1 dose-escalation study of S-222611, an oral reversible dual tyrosine kinase inhibitor of EGFR and HER2, in patients with solid tumours.

R. Plummer, E. Frenkel, S. Matsumoto, 2015, European journal of cancer.

Nuclear thymidylate synthase expression, p53 expression and 5FU response in colorectal carcinoma

P. Johnston, D. Longley, D. Jodrell, 2001, British Journal of Cancer.

Understanding the Complexity of Porous Graphitic Carbon (PGC) Chromatography: Modulation of Mobile-Stationary Phase Interactions Overcomes Loss of Retention and Reduces Variability

D. Jodrell, F. Richards, T. E. Bapiro, 2016, Analytical chemistry.

Aspirin activates the NF-κB signalling pathway and induces apoptosis in intestinal neoplasia in two in vivo models of human colorectal cancer

O. Sansom, L. Stark, A. Clarke, 2006 .

Recent developments in adjuvant chemotherapy for colorectal cancer.

D. Jodrell, G. Knowles, 1997, European journal of cancer care.

Phase I Study of Sequence-Selective Minor Groove DNA Binding Agent SJG-136 in Patients with Advanced Solid Tumors

R. Begent, P. Loadman, D. Hochhauser, 2009, Clinical Cancer Research.

Expression of V1A and GRP receptors leads to cellular transformation and increased sensitivity to substance-P analogue-induced growth inhibition

C. Haslett, D. Jodrell, T. Sethi, 2005, British Journal of Cancer.

Increased gastrin-releasing peptide (GRP) receptor expression in tumour cells confers sensitivity to [Arg6,D-Trp7,9,NmePhe8]-substance P (6–11)-induced growth inhibition

C. Haslett, J. Cummings, D. Jodrell, 2003, British Journal of Cancer.

substance P (6 -11)-induced growth inhibition

C. Haslett, J. Cummings, D. Jodrell, 2003 .

Population Pharmacokinetics and Pharmacodynamics of Doxorubicin and Cyclophosphamide in Breast Cancer Patients

D. Richel, J. Schellens, J. Beijnen, 2007, Clinical pharmacokinetics.

Tuning the reactivity of osmium(II) and ruthenium(II) arene complexes under physiological conditions.

Anna F. A. Peacock, P. Sadler, D. Jodrell, 2006, Journal of the American Chemical Society.

Direct histological processing of EUS biopsies enables rapid molecular biomarker analysis for interventional pancreatic cancer trials.

A. Jah, D. Tuveson, S. Davies, 2012, Pancreatology : official journal of the International Association of Pancreatology (IAP) ... [et al.].

Progress in pancreatic cancer: moving beyond gemcitabine?

D. Jodrell, B. Basu, 2012, Expert review of anticancer therapy.

Relationships between carboplatin exposure and tumor response and toxicity in patients with ovarian cancer.

P. Langenberg, J. Burroughs, D. Jodrell, 1992, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Use of adaptive control with feedback to individualize suramin dosing.

H. Scher, D. Jodrell, M. Egorin, 1992, Cancer research.

Gastrin‐releasing peptide is a potent vasodilator in humans

D. Jodrell, S. Clive, D. Webb, 2001, Clinical pharmacology and therapeutics.

Forearm blood flow and local responses to peptide vasodilators: a novel pharmacodynamic measure in the phase I trial of antagonist G, a neuropeptide growth factor antagonist.

J. Smyth, D. Jodrell, S. Clive, 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

Phase I trial of AEG35156 administered as a 7-day and 3-day continuous intravenous infusion in patients with advanced refractory cancer.

Stephen J. Morris, L. Aarons, M. Ranson, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Targeting of 5-aza-2′-deoxycytidine residues by chromatin-associated DNMT1 induces proteasomal degradation of the free enzyme

B. Ramsahoye, D. Jodrell, S. Din, 2010, Nucleic acids research.

Structure-activity relationships for cytotoxic ruthenium(II) arene complexes containing N,N-, N,O-, and O,O-chelating ligands.

P. Sadler, D. Jodrell, R. Aird, 2006, Journal of medicinal chemistry.

Phase I and clinical evaluation of a pharmacologically guided regimen of suramin in patients with hormone-refractory prostate cancer.

D. Jodrell, E. Zuhowski, S. Jacobs, 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

SPARC dependent collagen deposition and gemcitabine delivery in a genetically engineered mouse model of pancreas cancer

B. Sipos, D. Jodrell, V. Ellenrieder, 2019, EBioMedicine.

Quantifying cell cycle-dependent drug sensitivities in cancer using a high throughput synchronisation and screening approach

A. Lau, D. Jodrell, F. Richards, 2021, EBioMedicine.

health economic assessments Prognosis without treatment as a modifier in

D. Webb, R. Camidge, D. Jodrell, 2007 .

A clinical phase I and pharmacokinetic study of BBR 2778, a novel anthracenedione analogue, administered intravenously, 3 weekly.

J. Smyth, D. Jodrell, A. Bernareggi, 2000, European journal of cancer.

Targeting Carcinoembryonic Antigen with DNA Vaccination: On-Target Adverse Events Link with Immunologic and Clinical Outcomes

S. Halford, U. Şahin, D. Jodrell, 2016, Clinical Cancer Research.

Targeting Carcinoembryonic Antigen with DNA Vaccination: On-Target Adverse Events Link with Immunological and Clinical Outcomes Running Title: Anti-CEA DNA Fusion Vaccination

S. Halford, U. Şahin, D. Jodrell, 2016 .

Enhanced clearance of topoisomerase I inhibitors from human colon cancer cells by glucuronidation.

J. S. Macpherson, J. Cummings, J. Smyth, 2002, Biochemical pharmacology.

Factors influencing the cellular accumulation of SN-38 and camptothecin

Gillian Smith, J. S. Macpherson, J. Cummings, 2002, Cancer Chemotherapy and Pharmacology.

Scheduling nab-paclitaxel combined with gemcitabine as first-line treatment for metastatic pancreatic adenocarcinoma

D. Tuveson, J. Bridgewater, D. Jodrell, 2020, British Journal of Cancer.

The heterogeneous distribution of extracellular adenosine reveals a myeloid-dependent axis, shaping the immunosuppressive microenvironment in pancreatic ductal adenocarcinoma

D. Jodrell, B. P. Kaistha, F. Richards, 2022, bioRxiv.

The effect of cimetidine on the pharmacokinetics of epirubicin in patients with advanced breast cancer: preliminary evidence of a potentially common drug interaction.

L. Murray, D. Kerr, S. Kaye, 1998, Clinical oncology (Royal College of Radiologists (Great Britain)).

Determination of the glucuronide metabolites of the topoisomerase I inhibitors 7-Ethyl 10-hydroxycamptothecin (SN-38) and NU/ICRF 505 by high-performance liquid chromatography

J. Cummings, J. Smyth, D. Jodrell, 2002 .

Bolus/infusional 5-fluorouracil and folinic acid for metastatic colorectal carcinoma: are suboptimal dosages being used in the UK?

L. Murray, S. Kaye, D. Jodrell, 1994, British Journal of Cancer.

Cisplatin and carboplatin: a guide to administration

D. Jodrell, N. Lawson, A. McMurray, 1993 .

Utility of individualized carboplatin dosing alone and in combination regimens.

D. Jodrell, M. Egorin, Merrill J. Egorin, 1992, Seminars in oncology.

Modeling toxicity and response in carboplatin-based combination chemotherapy.

K. Swenerton, J. Burroughs, D. Jodrell, 1994, Seminars in oncology.

Suramin, an active drug for prostate cancer: interim observations in a phase I trial.

D. Jodrell, E. Zuhowski, M. Egorin, 1993, Journal of the National Cancer Institute.

Efficacy, safety, and cost of new anticancer drugs

A. Harris, D. Jodrell, J. Cassidy, 2002, BMJ : British Medical Journal.

Influence of the antacid Maalox on the pharmacokinetics of capecitabine in cancer patients

B. Reigner, D. Jodrell, J. Cassidy, 1999, Cancer Chemotherapy and Pharmacology.

Phase I Safety, Pharmacokinetics, and Inhibition of Src Activity Study of Saracatinib in Patients with Solid Tumors

J. Baselga, I. Chirivella, J. Tabernero, 2010, Clinical Cancer Research.

Defining the spatial distribution of extracellular adenosine revealed a myeloid-dependent immunosuppressive microenvironment in pancreatic ductal adenocarcinoma

D. Jodrell, B. P. Kaistha, F. Richards, 2022, bioRxiv.

A phase I study of the trinuclear platinum compound, BBR 3464, in combination with protracted venous infusional 5-fluorouracil in patients with advanced cancer

D. Bisset, D. Jodrell, J. Cassidy, 2004, Cancer Chemotherapy and Pharmacology.

A Phase 1 Study of AS1409, a Novel Antibody-Cytokine Fusion Protein, in Patients with Malignant Melanoma or Renal Cell Carcinoma

G. Acton, J. Spicer, D. Jodrell, 2011, Clinical Cancer Research.

Phase II trial and pharmacokinetic assessment of intravenous melphalan in patients with advanced prostate cancer

David C. Smith, D. Jodrell, E. Zuhowski, 2004, Cancer Chemotherapy and Pharmacology.

Suramin: development of a population pharmacokinetic model and its use with intermittent short infusions to control plasma drug concentration in patients with prostate cancer.

D. Jodrell, E. Zuhowski, M. Egorin, 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Suramin, an Active Drug for Prostate Cancer: Interim Observations in a Phase I Trial

D. Jodrell, E. Zuhowski, M. Egorin, 1993 .

Phase I study of accelerated FEC with granulocyte colony-stimulating factor (Lenograstim) support.

M. Williams, D. Bissett, S. Kaye, 1995, British Journal of Cancer.

Pharmacodynamic-pharmacokinetic relationships and therapeutic drug monitoring.

M. Ratain, D. Jodrell, K. Kobayashi, 1993, Cancer surveys.

Cancer Therapy : Clinical A Phase 1 Study of AS 1409 , a Novel Antibody-Cytokine Fusion Protein , in Patients with Malignant Melanoma or Renal Cell Carcinoma

G. Acton, J. Spicer, D. Jodrell, 2011 .

Targeted metabolomics identifies perturbations in amino acid metabolism that sub-classify patients with COPD.

J. Riley, D. Lomas, W. MacNee, 2012, Molecular bioSystems.

Phase II studies of BBR3464, a novel tri-nuclear platinum complex, in patients with gastric or gastro-oesophageal adenocarcinoma.

J. Carmichael, F. D. De Braud, D. Cameron, 2004, European journal of cancer.

P29 MECHANISMS OF VASCULAR ENDOTHELIAL GROWTH FACTOR INHIBITION INDUCED HYPERTENSION

I. Wilkinson, C. McEniery, D. Jodrell, 2018 .

Capecitabine (oral 5-fluorouracil pro-drug) treatment for colorectal carcinoma causing ischaemic chest pain

D. Jodrell, T. McGoldrick, S. Clive, 2009, BMJ Case Reports.

Influence of P-glycoprotein expression on in vitro cytotoxicity and in vivo antitumour activity of the novel pyrrolobenzodiazepine dimer SJG-136.

S. Guichard, J. S. Macpherson, D. Jodrell, 2005, European journal of cancer.

Influence of P-glycoprotein expression on cytotoxicity and antitumour activity of the novel pyrrolobenzodiazepine dimer SJG-136

S. Guichard, J. S. Macpherson, D. Jodrell, 2005 .

A phase I and pharmacological study of the matrix metalloproteinase inhibitor BB-3644 in patients with solid tumours

D. Talbot, D. Jodrell, L. Wall, 2004, British Journal of Cancer.

Structure-activity relationships of monomeric C2-aryl pyrrolo[2,1-c][1,4]benzodiazepine (PBD) antitumor agents.

T. Barata, M. Zloh, S. Neidle, 2010, Journal of medicinal chemistry.

Targeting melanoma’s MCL1 bias unleashes the apoptotic potential of BRAF and ERK1/2 pathway inhibitors

S. Cook, J. Dry, Paul D. Smith, 2019, Nature Communications.

Controlling ligand substitution reactions of organometallic complexes: tuning cancer cell cytotoxicity.

Erwin P. L. van der Geer, P. Sadler, S. Guichard, 2005, Proceedings of the National Academy of Sciences of the United States of America.

Design, Synthesis, and Biological Evaluation of an Allosteric Inhibitor of HSET that Targets Cancer Cells with Supernumerary Centrosomes

A. Bender, F. Gergely, J. Raff, 2013, Chemistry & biology.

Cancer Therapy : Clinical gH 2 AX Foci Formation as a Pharmacodynamic Marker of DNA Damage Produced by DNA Cross-Linking Agents : Results from 2 Phase I Clinical Trials of SJG-136 ( SG 2000 )

John A. Hartley, Tim Meyer, Daniel Hochhauser, 2013 .

γ-H2AX Foci Formation as a Pharmacodynamic Marker of DNA Damage Produced by DNA Cross-Linking Agents: Results from 2 Phase I Clinical Trials of SJG-136 (SG2000)

Tim Meyer, Daniel Hochhauser, I. Puzanov, 2012, Clinical Cancer Research.

Optimization of the Antitumor Activity of Sequence-specific Pyrrolobenzodiazepine Derivatives Based on their Affinity for ABC Transporters

S. Guichard, D. Jodrell, M. Kaliszczak, 2010, The AAPS Journal.

ABCB1 genetic polymorphism influences the pharmacology of the new pyrrolobenzodiazepine derivative SJG-136

S. Guichard, J. S. Macpherson, D. Jodrell, 2008, The Pharmacogenomics Journal.

Tumor-Induced IL-6 Reprograms Host Metabolism to Suppress Anti-tumor Immunity

D. Fearon, D. Jodrell, A. Coll, 2016, Cell metabolism.

Fibroblast drug scavenging increases intratumoural gemcitabine accumulation in murine pancreas cancer

T. Gress, D. Jodrell, V. Ellenrieder, 2017, Gut.

Targeting CXCL12 from FAP-expressing carcinoma-associated fibroblasts synergizes with anti–PD-L1 immunotherapy in pancreatic cancer

Derek S. Chan, James O. Jones, S. Teichmann, 2013, Proceedings of the National Academy of Sciences.

CTGF antagonism with mAb FG-3019 enhances chemotherapy response without increasing drug delivery in murine ductal pancreas cancer

C. Pilarsky, D. Tuveson, D. Jodrell, 2013, Proceedings of the National Academy of Sciences.

Hyaluronan impairs vascular function and drug delivery in a mouse model of pancreatic cancer

Derek S. Chan, D. Tuveson, J. Skepper, 2012, Gut.

CXCR4 inhibition in human pancreatic and colorectal cancers induces an integrated immune response

N. Rosenfeld, F. Gallagher, E. Godfrey, 2020, Proceedings of the National Academy of Sciences.

CHK1 Inhibition Synergizes with Gemcitabine Initially by Destabilizing the DNA Replication Apparatus.

D. Jodrell, F. Richards, R. Boyce, 2015, Cancer research.

Simultaneous determination of decitabine and vorinostat (Suberoylanalide hydroxamic acid, SAHA) by liquid chromatography tandem mass spectrometry for clinical studies.

S. Guichard, D. Jodrell, K. Patel, 2008, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

Antimicrobial practice. Development of guidelines for gentamicin dosing.

D. Jodrell, A. Thomson, S. Alcock, 1996, The Journal of antimicrobial chemotherapy.

Identification of a region of frequent loss of heterozygosity at 11q24 in colorectal cancer.

H. Gabra, A. Wyllie, J. Smyth, 1999, Cancer research.

Predictive in vivo animal models and translation to clinical trials.

Natalie Cook, D. Tuveson, D. Jodrell, 2012, Drug discovery today.

The Products of Pre-B Cell-specific Genes ( X 5 and Vp , . B ) and the Immunoglobulin iu Chain Form a Complex That Is Transported onto the Cell Surface

D. Tuveson, M. Reth, T. Tsubata, 2003 .

Anti-Tumour Efficacy of Capecitabine in a Genetically Engineered Mouse Model of Pancreatic Cancer

D. Tuveson, D. Jodrell, B. Krippendorff, 2013, PloS one.

Combenefit: an interactive platform for the analysis and visualization of drug combinations

Dennis Wang, Chiara Fornari, Giovanni Y. Di Veroli, 2016, Bioinform..

Loss of P53 Function Activates JAK2-STAT3 Signaling to Promote Pancreatic Tumor Growth, Stroma Modification, and Gemcitabine Resistance in Mice and Is Associated With Patient Survival.

S. Rose-John, M. Barenboim, O. Sansom, 2016, Gastroenterology.

Antisense Bcl-xl down-regulation switches the response to topoisomerase I inhibition from senescence to apoptosis in colorectal cancer cells, enhancing global cytotoxicity.

R. L. Hayward, J. S. Macpherson, J. Cummings, 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

The ATR Inhibitor AZD6738 Synergizes with Gemcitabine In Vitro and In Vivo to Induce Pancreatic Ductal Adenocarcinoma Regression

A. Lau, D. Jodrell, Sandra Bernaldo de Quirós Fernández, 2018, Molecular Cancer Therapeutics.

Capecitabine as adjuvant treatment for stage III colon cancer.

Markus Abt, Joseph McKendrick, Marek Pawlicki, 2005, The New England journal of medicine.

Stable XIAP knockdown clones of HCT116 colon cancer cells are more sensitive to TRAIL, taxanes and irradiation in vitro

S. Guichard, D. Jodrell, R. Mitter, 2009, Cancer Chemotherapy and Pharmacology.

mTORC2 Signaling Drives the Development and Progression of Pancreatic Cancer.

Jun Yu, S. Barry, N. Bardeesy, 2016, Cancer research.

GEMMs as preclinical models for testing pancreatic cancer therapies

O. Sansom, D. Jodrell, J. Morton, 2015, Disease Models & Mechanisms.

Mechanistic Distinctions between CHK1 and WEE1 Inhibition Guide the Scheduling of Triple Therapy with Gemcitabine.

D. Jodrell, Sandra Bernaldo de Quirós Fernández, F. Richards, 2018, Cancer research.

A quantitative FastFUCCI assay defines cell cycle dynamics at a single-cell level

S. Lyons, D. Jodrell, F. Richards, 2017, Journal of Cell Science.

Erratum: Suramin, an active drug for prostate cancer: Interim observations in a phase I trial (Journal of the National Cancer Institute (1993) 85 (611- 621))

D. Jodrell, M. Eisenberger, L. Reyno, 1994 .

Glucuronidation as a mechanism of intrinsic drug resistance in human colon cancer: reversal of resistance by food additives.

Jeffrey Cummings, John F Smyth, J. S. Macpherson, 2003, Cancer research.

A phase I trial of the γ-secretase inhibitor MK-0752 in combination with gemcitabine in patients with pancreatic ductal adenocarcinoma

Lisa V. Hampson, D. Tuveson, S. Halford, 2018, British Journal of Cancer.

Complete loss of ATM function augments replication catastrophe induced by ATR inhibition and gemcitabine in pancreatic cancer models

A. Lau, D. Jodrell, Sandra Bernaldo de Quirós Fernández, 2020, British Journal of Cancer.

Gamma secretase inhibition promotes hypoxic necrosis in mouse pancreatic ductal adenocarcinoma

D. Tuveson, D. Jodrell, K. Frese, 2012, The Journal of experimental medicine.

Quinidine as a resistance modulator of epirubicin in advanced breast cancer: mature results of a placebo-controlled randomized trial.

D. Kerr, D. Bissett, D. Jodrell, 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Opportunities for quantitative translational modelling in Oncology.

Juan A. Delgado-SanMartin, P. Vicini, R. Jena, 2020, Clinical pharmacology and therapeutics.

T Cell–Mediated Antitumor Immunity Cooperatively Induced By TGFβR1 Antagonism and Gemcitabine Counteracts Reformation of the Stromal Barrier in Pancreatic Cancer

Rebecca L. Sorber, M. Mehta, D. Jodrell, 2021, Molecular Cancer Therapeutics.

Cytosolic 5′-nucleotidase 1A is overexpressed in pancreatic cancer and mediates gemcitabine resistance by reducing intracellular gemcitabine metabolites

C. Pilarsky, D. Jodrell, J. Gaedcke, 2019, EBioMedicine.

SPARC independent drug delivery and antitumour effects of nab-paclitaxel in genetically engineered mice

Derek S. Chan, D. Tuveson, D. Jodrell, 2013, Gut.

Carboplatin in the treatment of metastatic carcinoid tumours and paraganglioma: a phase II study

I. Smith, D. Jodrell, Duncan I. Jodrell, 2008, Cancer Chemotherapy and Pharmacology.

New Model for Estimating Glomerular Filtration Rate in Patients With Cancer

S. Tavaré, S. Sammut, H. Earl, 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

An automated fitting procedure and software for dose-response curves with multiphasic features

Graham Mills, Siang Boon Koh, Chiara Fornari, 2015, Scientific Reports.

Mechanisms Underlying Vascular Endothelial Growth Factor Receptor Inhibition–Induced Hypertension

I. Wilkinson, C. Schönlieb, C. McEniery, 2021, Hypertension.

Validation of real-time reverse-transcription-polymerase chain reaction for quantification of capecitabine-metabolizing enzymes.

S. Guichard, J. S. Macpherson, D. Jodrell, 2006, Analytical biochemistry.

Cancer immunotherapy trial registrations increase exponentially but chronic immunosuppressive glucocorticoid therapy may compromise outcomes

D. Fearon, D. Jodrell, T. Janowitz, 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

Oral capecitabine as an alternative to i.v. 5-fluorouracil-based adjuvant therapy for colon cancer: safety results of a randomized, phase III trial.

W. Scheithauer, J. Zaluski, H. Burris, 2003, Annals of oncology : official journal of the European Society for Medical Oncology.

Anti-Tumour Effects of a Specific Anti-ADAM17 Antibody in an Ovarian Cancer Model In Vivo

D. Jodrell, F. Richards, G. Murphy, 2012, PloS one.

A randomised comparative trial of mitozantrone/methotrexate/mitomycin C (MMM) and cyclophosphamide/methotrexate/5 FU (CMF) in the treatment of advanced breast cancer.

I. Smith, D. Jodrell, J. Mckinna, 1991, British Journal of Cancer.

Identification of Resistance Pathways Specific to Malignancy Using Organoid Models of Pancreatic Cancer

D. Tuveson, Paul D. Smith, V. Corbo, 2019, Clinical Cancer Research.

Abstract P4-12-24: Phase I trial of S-222611, a dual tyrosine kinase inhibitor of EGFR and HER2, with preliminary evidence of efficacy in patients (pts) with heavily-pretreated HER2-positive metastatic breast cancer

R. Plummer, J. Spicer, D. Jodrell, 2013 .

A phase I study of S-222611 an oral reversible dual inhibitor of EGFR and HER2, in patients with solid tumors.

R. Plummer, E. Frenkel, M. Jamal-Hanjani, 2012 .

Paclitaxel and CYC3, an aurora kinase A inhibitor, synergise in pancreatic cancer cells but not bone marrow precursor cells

D. Zheleva, D. Jodrell, B. Krippendorff, 2012, British Journal of Cancer.

Multicenter Validation of the CamGFR Model for Estimated Glomerular Filtration Rate

S. Tavaré, H. Earl, J. Shamash, 2019, JNCI cancer spectrum.

Fate-mapping lymphocyte clones and their progenies from induced antigen-signals identifies temporospatial behaviours of T cells mediating tolerance

P. Lio’, K. Okkenhaug, D. Adams, 2023, bioRxiv.

A feasibility study of roquinimex (Linomide) and alpha interferon in patients with advanced malignant melanoma or renal carcinoma.

D. Jodrell, J. Cassidy, M. Mackean, 1998, British Journal of Cancer.

Abstract A123: Preclinical evaluation of dual mTOR inhibitor, AZD2014, in prostate cancer

D. Neal, J. Griffiths, B. Davies, 2015 .

Early Neutrophilia Marked by Aerobic Glycolysis Sustains Host Metabolism and Delays Cancer Cachexia

E. Wagner, M. Vacca, A. Venkitaraman, 2021, bioRxiv.

A phase I trial of the c-secretase inhibitor MK-0752 in combination with gemcitabine in patients with pancreatic ductal adenocarcinoma

Lisa V. Hampson, D. Tuveson, S. Halford, 2018 .

Phase I Clinical and Pharmacokinetic Study of Plitidepsin as a 1-Hour Weekly Intravenous Infusion in Patients with Advanced Solid Tumors

J. Smyth, D. Jodrell, J. Jimeno, 2008, Clinical Cancer Research.

Meeting Proceedings of the “Phase I: Where Science Becomes Medicine” Conference, Manchester, UK: Meeting Overview

R. Bristow, T. Illidge, F. Thistlethwaite, 2019 .

Impact of cyclophosphamide on relationships between carboplatin exposure and response or toxicity when used in the treatment of advanced ovarian cancer.

K. Swenerton, J. Burroughs, D. Jodrell, 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Early relapse on adjuvant gemcitabine associated with an exceptional response to 2nd line capecitabine chemotherapy in a patient with pancreatic adenosquamous carcinoma with strong intra-tumoural expression of cytidine deaminase: a case report

J. Risdall, D. Jodrell, S. Upponi, 2020, BMC cancer.

Clinical and biological markers predictive of treatment response associated with metastatic pancreatic adenocarcinoma

L. di Lisio, D. Jodrell, W. Qian, 2023, British Journal of Cancer.

A phase I trial of AEG35156 (XIAP antisense) administered as a continuous intravenous infusion in patients with advanced tumors.

M. Ranson, T. Ward, C. Dive, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

The impact of prognosis without treatment on doctors' and patients' resource allocation decisions and its relevance to new drug recommendation processes.

D. Webb, D. Camidge, D. Jodrell, 2008, British journal of clinical pharmacology.

Phase I study of AZD0530, an oral potent inhibitor of Src kinase: First demonstration of inhibition of Src activity in human cancers

J. Baselga, J. Tabernero, H. Hurwitz, 2007 .

Bolus/infusional 5-fluorouracil and folinic acid. A report on two prospective, consecutive phase II studies with 5-fluorouracil dose escalation.

D. Jodrell, C. Twelves, J. Cassidy, 1998, British Journal of Cancer.

A novel Phase I/IIa design for early phase oncology studies and its application in the evaluation of MK‐0752 in pancreatic cancer

John Whitehead, Thomas Jaki, Natalie Cook, 2012, Statistics in medicine.

Significant effect of capecitabine on the pharmacokinetics and pharmacodynamics of warfarin in patients with cancer.

B. Reigner, R. Camidge, D. Jodrell, 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Bombesin and Substance P Analogues Differentially Regulate G-protein Coupling to the Bombesin Receptor

Christopher Haslett, C. Haslett, D. Jodrell, 2001, The Journal of Biological Chemistry.

Bioequivalence of two tablet formulations of capecitabine and exploration of age, gender, body surface area, and creatinine clearance as factors influencing systemic exposure in cancer patients

B. Reigner, K. O'Byrne, D. Cameron, 1999, Cancer Chemotherapy and Pharmacology.

Phase 2 study of ABT-751 in patients with refractory metastatic colorectal carcinoma (CRC)

A. Benson, D. Jodrell, H. Kindler, 2005 .

TITLE: CHK1 inhibition synergizes with gemcitabine initially by destabilizing the DNA replication apparatus AUTHORS AND AFFILIATIONS:

D. Jodrell, R. Boyce, Francés, 2015 .

Epirubicin chemotherapy and advanced breast cancer after adjuvant CMF chemotherapy.

D. Bissett, S. Kaye, D. Jodrell, 1995, Clinical oncology (Royal College of Radiologists (Great Britain)).

The use of 131I-MIBG in the imaging of metastatic carcinoid tumours.

V. R. McCready, D. Jodrell, A. Irvine, 1988, British Journal of Cancer.

Modelling of the cancer cell cycle as a tool for rational drug development: A systems pharmacology approach to cyclotherapy

Giovanni Y. Di Veroli, Ian Goldlust, Frances M. Richards, 2017, PLoS Comput. Biol..

Effects of nitric oxide manipulation on the disposition of platinum in an experimental glioma model

I. Whittle, D. Jodrell, P. Kelly, 1998, Neuroreport.

The EGFR demonstrates linear signal transmission.

D. Oyarzún, D. Jodrell, B. Krippendorff, 2014, Integrative biology : quantitative biosciences from nano to macro.

SYMPTOMATIC HYPOCALCAEMIA AFTER TREATMENT WITH HIGH-DOSE AMINOHYDROXYPROPYLIDENE DIPHOSPHONATE

I. Smith, D. Jodrell, T. Iveson, 1987, The Lancet.

Abstract P4-14-26: Phase I expansion of S-222611, a reversible inhibitor of EGFR and HER2, in advanced solid tumors, including HER2-positive breast cancer patients with brain metastases

R. Plummer, E. Frenkel, A. Italiano, 2016 .

The use of error-category mapping in pharmacokinetic model analysis of dynamic contrast-enhanced MRI data

Martin J. Graves, Tim Eisen, David J. Lomas, 2015, Magnetic resonance imaging.

Expression of V1A and GRP receptors leads to cellular transformation and increased sensitivity to substance-P analogue-induced growth inhibition

C. Haslett, D. Jodrell, T. Sethi, 2005, British Journal of Cancer.

Increased gastrin-releasing peptide (GRP) receptor expression in tumour cells confers sensitivity to [Arg6,D-Trp7,9,NmePhe8]-substance P (6–11)-induced growth inhibition

C. Haslett, J. Cummings, D. Jodrell, 2003, British Journal of Cancer.

Gamma secretase inhibition promotes hypoxic necrosis in mouse pancreatic ductal adenocarcinoma

D. Tuveson, D. Jodrell, K. Frese, 2012, The Journal of experimental medicine.

Defining the spatial distribution of extracellular adenosine revealed a myeloid-dependent immunosuppressive microenvironment in pancreatic ductal adenocarcinoma

D. Jodrell, B. P. Kaistha, F. Richards, 2023, Journal for ImmunoTherapy of Cancer.

Phase IClinical and Pharmacokinetic Study of Plitidepsin as a 1-Hour Weekly Intravenous Infusion in Patientswith Advanced SolidTumors

J. Smyth, D. Jodrell, M. Garci, 2008 .

Comparison of Iterative-Two Stage and Bootstrap Sampling Approaches in the Development of a Population Pharmacokinetic Model

D. Jodrell, M. Egorin, M. Eisenberger, 1997 .

GEMMs as preclinical models for testing pancreatic cancer therapies

O. Sansom, D. Jodrell, J. Morton, 2015, Disease Models & Mechanisms.

Phase I Study of Sequence-Selective Minor Groove DNA Binding Agent SJG-136 in Patients with Advanced Solid Tumors

R. Begent, P. Loadman, D. Hochhauser, 2009, Clinical Cancer Research.

Public and patient involvement: a survey on knowledge, experience and opinions among researchers within a precision oncology European project

Katherine E. Honan, S. Fröhling, R. Schlenk, 2023, BMC Cancer.

Anti-tumour activity in non-small cell lung cancer models and toxicity profiles for novel ruthenium(II) based organo-metallic compounds.

P. Sadler, S. Guichard, D. Jodrell, 2006, Biochemical pharmacology.

ICI D1694, an inhibitor of thymidylate synthase for clinical study.

D. Jodrell, A. Jackman, T. Stephens, 1991, Advances in experimental medicine and biology.